glp-1 intestine Receptor Agonists in Gastrointestinal Practices: Enhancing Both Procedural and Patient-Related Outcomes | SN Comprehensive Clinical Medicine GLP-1 isn't just an incretin
Description
Cell Metabolism, 27, 740 to 756
Realworld studies demonstrate high discontinuation rates of GLP1RAs by up to 75% within the first year of use, predominantly driven by side effects 20-22
Long-term habits commonly include: Although the adjustment period can feel intense initially, many bariatric patients report that these habits gradually become routine over time
While no GLP-1 medication currently carries FDA approval specifically for fatty liver disease, accumulating evidence supports their therapeutic potential through weight loss, improved insulin sensitivity, and reduced systemic inflammation
Thats where fiber comes in
They may recommend a trial period where you switch to three times weekly while monitoring your weight and appetite patterns
